{
    "organizations": [],
    "uuid": "971a408ba1a1b48a92b3480b9cf13d759b32a3b4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-titan-in-discussions-with-braeburn/brief-titan-in-discussions-with-braeburn-regarding-u-s-probuphine-commercialization-idUSFWN1PH0FY",
    "ord_in_thread": 0,
    "title": "BRIEF-Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 22, 2018 / 12:05 PM / in 6 minutes BRIEF-Titan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization Reuters Staff \nTitan Pharmaceuticals Inc: \n* TITAN IN DISCUSSIONS WITH BRAEBURN REGARDING U.S. PROBUPHINE® COMMERCIALIZATION \n* TITAN PHARMACEUTICALS - ‍HAS BEEN IN PRELIMINARY DISCUSSIONS WITH BRAEBURN FOR RETURN OF U.S. COMMERCIALIZATION RIGHTS TO PROBUPHINE​ \n* TITAN PHARMACEUTICALS - ‍HAS RETAINED CANACCORD GENUITY TO ASSIST IN EFFORT AS PART OF EVALUATION OF STRATEGIC AND FINANCIAL ALTERNATIVES​ \n* TITAN PHARMACEUTICALS - ‍BELIEVES IT IS APPROPRIATE TO SEEK A NEW PARTNER THAT CAN BETTER FOCUS ON SUCCESSFUL COMMERCIALIZATION STRATEGY FOR PROBUPHINE​ \n* TITAN PHARMACEUTICALS - BRAEBURN‘S RECEIPT OF CRL FROM U.S. FDA FOR BUPRENORPHINE PRODUCT NDA LIKELY TO NEGATIVELY IMPACT ITS PROBUPHINE MARKETING Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T14:04:00.000+02:00",
    "crawled": "2018-01-22T15:01:32.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "discussion",
        "braeburn",
        "regarding",
        "commercialization",
        "reuters",
        "staff",
        "titan",
        "pharmaceutical",
        "inc",
        "titan",
        "discussion",
        "braeburn",
        "regarding",
        "commercialization",
        "titan",
        "pharmaceutical",
        "preliminary",
        "discussion",
        "braeburn",
        "return",
        "commercialization",
        "right",
        "titan",
        "pharmaceutical",
        "retained",
        "canaccord",
        "genuity",
        "assist",
        "effort",
        "part",
        "evaluation",
        "strategic",
        "financial",
        "titan",
        "pharmaceutical",
        "appropriate",
        "seek",
        "new",
        "partner",
        "better",
        "focus",
        "successful",
        "commercialization",
        "strategy",
        "titan",
        "pharmaceutical",
        "braeburn",
        "receipt",
        "crl",
        "fda",
        "buprenorphine",
        "product",
        "nda",
        "likely",
        "negatively",
        "impact",
        "probuphine",
        "marketing",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}